- Report
- November 2026
- 274 Pages
Global
From €5466EUR$5,850USD£4,566GBP
- Report
- November 2026
- 382 Pages
Global
From €5466EUR$5,850USD£4,566GBP
- Report
- November 2026
- 506 Pages
Global
From €5466EUR$5,850USD£4,566GBP
- Report
- February 2026
- 250 Pages
Global
From €4195EUR$4,490USD£3,505GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1869EUR$2,000USD£1,561GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1869EUR$2,000USD£1,561GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1869EUR$2,000USD£1,561GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1168EUR$1,250USD£976GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1168EUR$1,250USD£976GBP
- Report
- September 2022
- 30 Pages
Global
From €2570EUR$2,750USD£2,147GBP
- Report
- August 2022
- 30 Pages
Global
From €3037EUR$3,250USD£2,537GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2606EUR$2,789USD£2,177GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2606EUR$2,789USD£2,177GBP
- Report
- May 2024
- 134 Pages
Global
From €3737EUR$3,999USD£3,122GBP
- Report
- August 2024
- 78 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- March 2024
- 96 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- May 2022
- 95 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- December 2022
- 42 Pages
Global
From €3270EUR$3,500USD£2,732GBP
- Report
- October 2022
- 41 Pages
Global
From €3270EUR$3,500USD£2,732GBP
- Report
- October 2022
- 69 Pages
Global
From €3270EUR$3,500USD£2,732GBP

The Glutamate Receptor market is a subset of the Central Nervous System Drugs market. Glutamate Receptors are proteins found in the brain and are responsible for the majority of excitatory neurotransmission. They are involved in a variety of neurological processes, including learning, memory, and cognition. As such, they are a target for drug development, with the aim of treating neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy.
The Glutamate Receptor market is highly competitive, with a number of large pharmaceutical companies and biotechnology firms vying for market share. Companies in the market include Merck, Pfizer, Novartis, Eli Lilly, and AstraZeneca. Additionally, there are a number of smaller companies, such as Neurocrine Biosciences, that are developing drugs targeting Glutamate Receptors. Show Less Read more